Skip to content

Study · Randomized controlled trial · n = 108 · 2019

6 results

Efficacy and safety of lixisenatide as add-on therapy to basal insulin in older adults with type 2 diabetes in the GetGoal-O Study.

Dailey GE, Dex TA, Roberts M, Liu M, Meneilly GS

Journal of diabetes26 Jun 2019Cited by 7 (Europe PMC)

PMID31094074 (opens in a new tab)PMCIDPMC6899823 (opens in a new tab)DOI10.1111/1753-0407.12952 (opens in a new tab)PepBankPUB-31094074
Read at sourcePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In older adults with diabetes, more patients achieved composite endpoints with lixisenatide than placebo.

    In plain wordsIn older adults with diabetes, more patients achieved composite endpoints with lixisenatide than placebo.

    Peptide
    Lixisenatide
    Outcome
    IncreaseComposite endpoint achievement
    Study

    n = 108

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    20 μg once daily · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    A greater proportion of patients treated with lixisenatide than placebo achieved composite endpoints.
    1 context sentence
    Summary · context
    This post hoc analysis evaluated data from non-frail patients with T2D inadequately controlled on BI with or without oral antidiabetic drugs (n = 108), randomized to once-daily lixisenatide 20 μg or placebo for 24 weeks (GetGoal-O Study).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In older adults with diabetes, lixisenatide reduced HbA1c, 2-hour PPG, average seven-point SMPG, and body weight significantly more than placebo.

    In plain wordsIn older adults with diabetes, lixisenatide reduced HbA1c, post-meal glucose, average self-monitored glucose, and body weight significantly more than placebo.

    Peptide
    Lixisenatide
    Outcome
    DecreaseHbA1c, postprandial glucose, SMPG and body weight
    Study

    n = 108

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    20 μg once daily · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Compared with placebo, lixisenatide-treated patients had significantly greater reductions in HbA1c, 2-hour PPG, average seven-point SMPG, and body weight.
    1 context sentence
    Summary · context
    This post hoc analysis evaluated data from non-frail patients with T2D inadequately controlled on BI with or without oral antidiabetic drugs (n = 108), randomized to once-daily lixisenatide 20 μg or placebo for 24 weeks (GetGoal-O Study).
  3. 03HumanRandomized controlled trialSafety outcome

    In older adults with diabetes, symptomatic hypoglycemia occurred in 5.7% with lixisenatide versus 12.7% with placebo.

    In plain wordsIn older adults with diabetes, symptomatic hypoglycemia occurred in 5.7% with lixisenatide versus 12.7% with placebo.

    Peptide
    Lixisenatide
    Outcome
    DecreaseDocumented symptomatic hypoglycemia
    Study

    n = 108

    Comparator
    Placebo
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    20 μg once daily · 24 weeksAs given in this study (human).

    Measurements

    Hypoglycemia incidence
    5.7%
    lixisenatide
    Hypoglycemia incidence
    12.7%
    placebo

    Source sentences

    Summary
    Documented symptomatic hypoglycemia was approximately two-fold higher in patients treated with placebo than lixisenatide (12.7% vs 5.7%).
    1 context sentence
    Summary · context
    This post hoc analysis evaluated data from non-frail patients with T2D inadequately controlled on BI with or without oral antidiabetic drugs (n = 108), randomized to once-daily lixisenatide 20 μg or placebo for 24 weeks (GetGoal-O Study).
  4. 04HumanRandomized controlled trialSafety outcome

    In older adults with diabetes, gastrointestinal adverse events occurred in 34% with lixisenatide versus 9.1% with placebo.

    In plain wordsIn older adults with diabetes, gastrointestinal adverse events occurred in 34% with lixisenatide versus 9.1% with placebo.

    Peptide
    Lixisenatide
    Outcome
    IncreaseGastrointestinal treatment-emergent adverse events
    Study

    n = 108

    Comparator
    Placebo
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    20 μg once daily · 24 weeksAs given in this study (human).

    Measurements

    GI TEAE incidence
    34%
    lixisenatide
    GI TEAE incidence
    9.1%
    placebo

    Source sentences

    Summary
    GI TEAEs occurred more frequently in the lixisenatide- than placebo-treated group (34% vs 9.1%).
    1 context sentence
    Summary · context
    This post hoc analysis evaluated data from non-frail patients with T2D inadequately controlled on BI with or without oral antidiabetic drugs (n = 108), randomized to once-daily lixisenatide 20 μg or placebo for 24 weeks (GetGoal-O Study).
  5. 05HumanObservational studyEfficacy outcome

    In older adults with diabetes, moderate renal insufficiency did not negatively affect lixisenatide efficacy.

    In plain wordsIn older adults with diabetes, moderate renal insufficiency was not linked to worse lixisenatide efficacy.

    Peptide
    Lixisenatide
    Outcome
    Not applicableEfficacy with moderate renal insufficiency
    Study

    n: not reported in source

    Comparator
    Patients without moderate renal insufficiency
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    20 μg once daily · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Moderate renal insufficiency (estimated glomerular filtration rate between ≥30 and 2 ) did not negatively affect lixisenatide efficacy or safety.
    1 context sentence
    Summary · context
    This post hoc analysis evaluated data from non-frail patients with T2D inadequately controlled on BI with or without oral antidiabetic drugs (n = 108), randomized to once-daily lixisenatide 20 μg or placebo for 24 weeks (GetGoal-O Study).
  6. 06HumanObservational studySafety outcome

    In older adults with diabetes, moderate renal insufficiency did not negatively affect lixisenatide safety.

    In plain wordsIn older adults with diabetes, moderate renal insufficiency was not linked to worse lixisenatide safety.

    Peptide
    Lixisenatide
    Outcome
    Not applicableSafety with moderate renal insufficiency
    Study

    n: not reported in source

    Comparator
    Patients without moderate renal insufficiency
    Outcome group
    Adverse events · Whole body
    Studied dose
    20 μg once daily · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Moderate renal insufficiency (estimated glomerular filtration rate between ≥30 and 2 ) did not negatively affect lixisenatide efficacy or safety.
    1 context sentence
    Summary · context
    This post hoc analysis evaluated data from non-frail patients with T2D inadequately controlled on BI with or without oral antidiabetic drugs (n = 108), randomized to once-daily lixisenatide 20 μg or placebo for 24 weeks (GetGoal-O Study).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.